Clinical trials: CINV, open to volunteers
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as…
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea, Vomiting, Neoplasms
- Trial name
- HR20013-RWS (NCT07874308)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-Induced Nausea and Vomiting (CINV)
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase.
- Trial name
- NCT07726433
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Multiple Myeloma
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose…
- Trial name
- NCT07413809
- Testing
- Fosaprepitant, Tropisetron, Olanzapine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Chemotherapy Induced Nausea and Vomiting
Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia
This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea…
- Trial name
- NCT06756022
- Testing
- Dolasetron mesylate injection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Anhui Provincial Children's Hospital
Breast Cancer, Aromatherapy
Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy
This phase III, multicenter, randomized, open-label trial evaluates whether aromatherapy plus standard antiemetic therapy improves complete response (CR) of CINV compared with standard therapy alone in breast cancer patients…
- Conditions
- Breast Cancer, Aromatherapy, Chemotherapy, CINV
- Trial name
- NCT07761325
- Testing
- Aromatherapy, Standard triple antiemetic therapy
- Volunteers
- 374 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Multiple Myeloma, Autologous Stem Cell Transplantation
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy.
- Trial name
- FONDO-LOW (NCT06588413)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Augusta University
Nausea and Vomiting
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical…
- Trial name
- TSEPHCC (NCT05690802)
- Testing
- Palonosetron hydrochloride capsules
- Where
- China
- Volunteers
- 1,060 people
- Sponsor
- Xijing Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV)
Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting
The primary objective of this clinical study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with a 5-HT3 receptor antagonist for the prophylaxis of nausea and vomiting caused by moderately…
- Trial name
- NCT07246070
- Testing
- nanocrystalline megestrol acetate combined with ondansetron, dexamethasone combined with ondansetron
- Volunteers
- 127 people
- Sponsor
- AIPING ZHOU
Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation.
- Trial name
- NCT07747194
- Testing
- Acupuncture, Conventional care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiao Wang
Chemotherapy Induced Nausea and Vomiting
This Study Will Investigate the Effectiveness of Peppermint Oil Inhalation in Reducing the Intensity and Frequency of Acute Nausea and Vomiting Among Cancer Patients Undergoing Chemotherapy. Chemotherapy-induced Nausea and Vomiting (CINV) Are Among the Most Distressing Side Effects Experienced by pa
Cancer is a major cause of death and disability worldwide and in South Asian countries. Cancer treatment options include chemotherapy, radiation therapy, surgery, and adjuvant therapy (Additional treatments after primary cancer…
- Trial name
- NCT06950632
- Testing
- Pepppermint oil inhalation
- Where
- Pakistan
- Volunteers
- 106 people
- Sponsor
- University of Health Sciences Lahore
Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Chemotherapy is one of the most common treatments for breast cancer, but the adverse effects can be severe enough to delay or make chemotherapy intolerable, thus affecting the efficacy of the disease.
- Trial name
- NCT05841849
- Testing
- Aprepitant, Palonosetron, Fosaprepitant
- Where
- China
- Volunteers
- 1,028 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment.
- Trial name
- Aroma-CINV (NCT07209501)
- Testing
- Aromatherapy inhaler
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Chemotherapy-induced Nausea and Vomiting
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most common and distressing adverse effects in patients receiving highly emetogenic chemotherapy (HEC).
- Trial name
- AACINV (NCT07760766)
- Testing
- Auricular Acupressure
- Where
- China
- Volunteers
- 332 people
- Sponsor
- China Medical University, China
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA